COLORADO SPRINGS, Colo.--(BUSINESS WIRE)--Cannabis Science (OTCBB:CBIS), a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges is pleased to report on the continued progress made by Patient Three who suffers from an extremely severe case of chemo- and radiation-resistant squamous cell carcinoma.
